News

Silence Therapeutics has announced collaboration with Hansoh Pharmaceutical to develop new therapeutics using Silence’s mRNAi GOLD platform. As part of the collaboration, the companies will develop novel short

Exelixis has signed an exclusive collaboration and license agreement with STORM Therapeutics to discover and develop inhibitors of novel RNA modifying enzymes. Initially, the companies will focus on

Intellia Therapeutics, and SparingVision have entered into a strategic collaboration to develop new genomic medicines making use of CRISPR/Cas9 technology to treat ocular diseases. A clinical-stage genome editing

The US Food and Drug Administration (FDA) has approved biologics license application (sBLA) and the European Medicines Agency (EMA) has validated the type-II variation application for Novartis’ Beovu

Poseida Therapeutics has signed a research collaboration and license agreement with Takeda Pharmaceutical Company to develop up to eight in vivo gene therapy programmes. They will focus on

Pacira BioSciences has signed a definitive agreement to acquire biopharmaceutical firm Flexion Therapeutics to strengthen its position in non-opioid pain management. Founded in 2007, Flexion is focused on

Brii Biosciences has filed an emergency use authorization (EUA) application for its investigational SARS-CoV-2 monoclonal antibody combination therapy, BRII-196/BRII-198, to the US Food and Drug Administration (FDA). Obtained

As per the deal, Samsung Biologics will offer end-to-end CDMO services including cell line development, clinical drug substance and drug product production services. Samsung Biologics’ development and production

The acquisition is in accordance with the development, option and stock purchase agreement (DOSPA) entered by Fortress Biotech, Caelum, Alexion and others. Biopharmaceutical company Fortress founded Caelum, which